Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
31 July, 2015 01:45 IST
Dr Reddys gets USFDA nod for Sildenafil tablets
Source: IRIS | 19 Nov, 2012, 09.43AM
Comments  |  Post Comment

Dr Reddys Laboratories, an integrated global pharmaceutical company,  announced that it has launched Sildenafil tablets (20 mg), a bioequivalent generic version of Revatio (Sildenafil) tablets in the US market.

It has received approval by the United States Food & Drugs Administration (USFDA) for ANDA Sildenafil tablets.

The Revatio brand had US sales of approximately USD 338.67 million for the most recent 12 months ending September 2012 according to IMS health.

Shares of the company gained Rs 16, or 0.91%, to trade at Rs 1,773.35. The total volume of shares traded was 755 at the BSE (9.32 a.m., Monday).



Dr Reddy`S Laboratories Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Exide Industries quarterly net declines 16.24% - 30-Jul-2015 18:17
Gujarat Pipavav Port quarterly profit drops 0.14% - 30-Jul-2015 18:10
Gati quarterly earnings drop 31.91% - 30-Jul-2015 17:41
G M M Pfaudler quarterly profit declines 10.94% - 30-Jul-2015 17:35
Colgate-Palmolive board recommends 1:1 bonus issue - 30-Jul-2015 17:27
Reliance Power files writ petition in Delhi HC against coal block cancellation - 30-Jul-2015 17:20
Dena Bank Q1 profit plummets 81.4% - 30-Jul-2015 17:11
Thomas Cook arm acquires Luxe Asia - 30-Jul-2015 17:06
HCC quarterly profit plunges 70.4% - 30-Jul-2015 16:56
SSWL to invest Rs 550 mn to set up hot rolling mill - 30-Jul-2015 16:33
Mahindra names new sports utility vehicle as TUV300 - 30-Jul-2015 16:27
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer